Assessment of sirolimus-eluting coronary stent implantation with aspirin plus low dose ticlopidine administration - One year results from CYPHER stent Japan Post-Marketing Surveillance Registry (J-PMS)

Circulation Journal

Volumn 73, Issue 6, 2009, Pages 1038-1044

  Ikari, Yuji ^a   Kotani, Junichi ^b   Kozuma, Ken ^c   Kyo, Eishou ^d   Nakamura, Masato ^e   Yokoi, Hiroyoshi ^f  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^c TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d Shiga Heart Center   (Japan)

^e TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f KOKURA MEMORIAL HOSPITAL   (Japan)

Author keywords

Antiplatelet therapy; Coronary disease; Drug eluting stents; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; INSULIN; RAPAMYCIN; TICLOPIDINE;

AGED; AGRANULOCYTOSIS; ANGIOCARDIOGRAPHY; ARTICLE; BIOCHEMISTRY; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; DIABETES MELLITUS; DISEASE DURATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG ELUTING STENT; DRUG ERUPTION; DRUG SAFETY; FEMALE; HEART DEATH; HEART INFARCTION; HEART INJURY; HEART MUSCLE REVASCULARIZATION; HEMODIALYSIS; HUMAN; IMPLANTATION; INTRAVASCULAR ULTRASOUND; JAPAN; KIDNEY DYSFUNCTION; LIVER DISEASE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; POSTMARKETING SURVEILLANCE; RISK REDUCTION; SIDE EFFECT; STENT THROMBOSIS; TARGET LESION REVASCULARIZATION; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME;

AGED; ASPIRIN; COMBINED MODALITY THERAPY; CORONARY ANGIOGRAPHY; CORONARY THROMBOSIS; CORONARY VESSELS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PRODUCT SURVEILLANCE, POSTMARKETING; REGISTRIES; SIROLIMUS; TICLOPIDINE; TREATMENT OUTCOME; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 67649975510     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-08-0732     Document Type: Article

References (43)

1. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773-1780. (Pubitemid 34586912)
2. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315-1323. (Pubitemid 37186209)
3. Holmes DR Jr, Leon MB, Moses JW, Popma JJ, Cutlip D, Fitzgerald PJ, et al. Analysis of 1-year clinical outcomes in the SIRIUS trial: A randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation 2004; 109: 634-640. (Pubitemid 38198871)
4. Schofer J, Schluter M, Gershlick AH, Wijns W, Garcia E, Schampaert E, et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: Double-blind, randomised controlled trial (E-SIRIUS). Lancet 2003; 362: 1093-1099. (Pubitemid 37222332)
5. Schampaert E, Cohen EA, Schluter M, Reeves F, Traboulsi M, Title LM, et al. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol 2004; 43: 1110-1115. (Pubitemid 38352997)
6. Schampaert E, Moses JW, Schofer J, Schluter M, Gershlick AH, Cohen EA, et al. Sirolimus-eluting stents at two years: A pooled analysis of SIRIUS, E-SIRIUS, and C-SIRIUS with emphasis on late revascularizations and stent thromboses. Am J Cardiol 2006; 98: 36-41. (Pubitemid 43902677)
7. Urban P, Gershlick AH, Guagliumi G, Guyon P, Lotan C, Schofer J, et al. Safety of coronary sirolimus-eluting stents in daily clinical practice: One-year follow-up of the e-Cypher registry. Circulation 2006; 113: 1434-1441. (Pubitemid 43739440)
8. Lemos PA, Serruys PW, van Domburg RT, Saia F, Arampatzis CA, Hoye A, et al. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world": The Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation 2004; 109: 190-195.
9. Bavry AA, Kumbhani DJ, Helton TJ, Bhatt DL. Risk of thrombosis with the use of sirolimus-eluting stents for percutaneous coronary intervention (from registry and clinical trial data). Am J Cardiol 2005; 95: 1469-1472. (Pubitemid 40824771)
10. Berger PB, Bell MR, Rihal CS, Ting H, Bareness G, Garratt K, et al. Clopidogrel versus ticlopidine after intracoronary stent placement. J Am Coll Cardiol 1999; 34: 1891-1894. (Pubitemid 30002640)
11. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: The clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000; 102: 624-629. (Pubitemid 30640661)
12. Bhatt DL, Bertrand ME, Berger PB, L'Allier PL, Moussa I, Moses JW, et al. Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. J Am Coll Cardiol 2002; 39: 9-14. (Pubitemid 34059855)
13. Muller C, Buttner HJ, Petersen J, Roskamm H. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents. Circulation 2000; 101: 590-593. (Pubitemid 30094727)
14. Juergens CP, Wong AM, Leung DY, Lowe HC, Lo S, Fernandes C, et al. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after coronary stent implantation. Am Heart J 2004; 147: E15. (Pubitemid 38900457)
15. Grines CL, Bonow RO, Casey DE Jr, Gardner TJ, Lockhart PB, Moliterno DJ, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: A science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation 2007; 115: 813-818. (Pubitemid 46294748)
16. Thebault JJ, Blatrix CE, Blanchard JF, Panak EA. Effects of ticlopidine, a new platelet aggregation inhibitor in man. Clin Pharmacol Ther 1975; 18: 485-490.
17. David JL, Monfort F, Herion F, Raskinet R. Compared effects of three dose-levels of ticlopidine on platelet function in normal subjects. Thromb Res 1979; 14: 35-49. (Pubitemid 9108078)
18. Picard-Fraire C. Ticlopidine hydrochloride: Relationship between dose, kinetics, plasma concentration and effect on platelet function. Thromb Res Suppl 1983; 4: 119-128.
19. Ruan C, Destelle G, Wang Z, Wan H, He Y, Cheng D, et al. Ticlopidine in China: Comparative study on the effect of two dose levels on bleeding time and platelet function in healthy volunteers. Haemostasis 1989; 19: 94-99. (Pubitemid 19095127)
20. Fukuuchi Y, Tohgi H, Okudera T, Ikeda Y, Miyanaga Y, Uchiyama S, et al. A randomized, double-blind study comparing the safety and efficacy of clopidogrel versus ticlopidine in Japanese patients with noncardioembolic cerebral infarction. Cerebrovasc Dis 2008; 25: 40-49. (Pubitemid 351280374)
21. Steg PG, Bhatt DL, Wilson PW, D'Agostino R Sr, Ohman EM, Rother J, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 2007; 297: 1197-1206. (Pubitemid 46465728)
22. Fukushima K, Kobayashi Y, Okuno T, Nakamura Y, Sakakibara M, Nakayama T, et al. Incidence of side-effects of ticlopidine after sirolimus-eluting stent implantation. Circ J 2007; 71: 617-619.
23. Iwata Y, Kobayashi Y, Fukushima K, Kitahara H, Asano T, Ishio N, et al. Incidence of premature discontinuation of antiplatelet therapy after sirolimus-eluting stent implantation. Circ J 2008; 72: 340-341.
24. Morice MC, Colombo A, Meier B, Serruys P, Tamburino C, Guagliumi G, et al. Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: The REALITY trial: A randomized controlled trial. JAMA 2006; 295: 895-904. (Pubitemid 43295824)
25. Saia F, Piovaccari G, Manari A, Santarelli A, Benassi A, Aurier E, et al. Clinical outcomes for sirolimus-eluting stents and polymer-coated paclitaxel-eluting stents in daily practice: Results from a large multicenter registry. J Am Coll Cardiol 2006; 48: 1312-1318. (Pubitemid 44436800)
26. Abbott JD, Vlachos HA, Selzer F, Sharaf BL, Holper E, Glaser R, et al. Gender-based outcomes in percutaneous coronary intervention with drug-eluting stents (from the National Heart, Lung, and Blood Institute Dynamic Registry). Am J Cardiol 2007; 99: 626-631. (Pubitemid 46273298)
27. Turco MA, Ormiston JA, Popma JJ, Mandinov L, O'Shaughnessy CD, Mann T, et al. Polymer-based, paclitaxel-eluting TAXUS Liberte stent in de novo lesions: The pivotal TAXUS ATLAS trial. J Am Coll Cardiol 2007; 49: 1676-1683. (Pubitemid 46589927)
28. Williams DO, Abbott JD, Kip KE. Outcomes of 6906 patients undergoing percutaneous coronary intervention in the era of drug-eluting stents: Report of the DEScover Registry. Circulation 2006; 114: 2154-2162. (Pubitemid 44747896)
29. Abizaid A, Chan C, Lim YT, Kaul U, Sinha N, Patel T, et al. Twelve-month outcomes with a paclitaxel-eluting stent transitioning from controlled trials to clinical practice (the WISDOM Registry). Am J Cardiol 2006; 98: 1028-1032. (Pubitemid 44486137)
30. Zahn R, Hamm CW, Schneider S, Zeymer U, Nienaber CA, Richardt G, et al. Incidence and predictors of target vessel revascularization and clinical event rates of the sirolimus-eluting coronary stent (results from the prospective multicenter German Cypher Stent Registry). Am J Cardiol 2005; 95: 1302-1308. (Pubitemid 40719860)
31. Windecker S, Remondino A, Eberli FR, Juni P, Raber L, Wenaweser P, et al. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med 2005; 353: 653-662. (Pubitemid 41175673)
32. Kumar S, Suresh V, Prendergast BD, Brooks NH, Wicks P, Levy RD, et al. Outcome in the real-world of coronary high-risk intervention with drug-eluting stents (ORCHID) - a single-center study comparing Cypher sirolimus-eluting with Taxus paclitaxel-eluting stents. Catheter Cardiovasc Interv 2006; 68: 663-668. (Pubitemid 44721083)
33. Takahashi S, Kaneda H, Tanaka S, Miyashita Y, Shiono T, Taketani Y, et al. Late angiographic stent thrombosis after sirolimus-eluting stent implantation. Circ J 2007; 71: 226-228. (Pubitemid 46182697)
34. Hur SH, Kitamura K, Morino Y, Honda Y, Jones M, Korr KS, et al. Efficacy of postdeployment balloon dilatation for current generation stents as assessed by intravascular ultrasound. Am J Cardiol 2001; 88: 1114-1119. (Pubitemid 33043841)
35. Brodie BR, Cooper C, Jones M, Fitzgerald P, Cummins F. Is adjunctive balloon postdilatation necessary after coronary stent deployment? Final results from the POSTIT trial. Catheter Cardiovasc Interv 2003; 59: 184-192. (Pubitemid 36665948)
36. Blackman DJ, Porto I, Shirodaria C, Channon KM, Banning AP. Usefulness of high-pressure post-dilatation to optimize deployment of drug-eluting stents for the treatment of diffuse in-stent coronary restenosis. Am J Cardiol 2004; 94: 922-925. (Pubitemid 39349558)
37. Hoffmann R, Guagliumi G, Musumeci G, Reimers B, Petronio AS, Disco C, et al. Vascular response to sirolimus-eluting stents delivered with a nonaggressive implantation technique: Comparison of intravascular ultrasound results from the multicenter, randomized E-SIRIUS, and SIRIUS trials. Catheter Cardiovasc Interv 2005; 66: 499-506. (Pubitemid 41779015)
38. Fitzgerald PJ, Oshima A, Hayase M, Metz JA, Bailey SR, Baim DS, et al. Final results of the Can Routine Ultrasound Influence Stent Expansion (CRUISE) study. Circulation 2000; 102: 523-530. (Pubitemid 30639970)
39. Oemrawsingh PV, Mintz GS, Schalij MJ, Zwinderman AH, Jukema JW, van der Wall EE. Intravascular ultrasound guidance improves angiographic and clinical outcome of stent implantation for long coronary artery stenoses: Final results of a randomized comparison with angiographic guidance (TULIP Study). Circulation 2003; 107: 62-67. (Pubitemid 36070934)
40. Sonoda S, Morino Y, Ako J, Terashima M, Hassan AH, Bonneau HN, et al. Impact of final stent dimensions on long-term results following sirolimus-eluting stent implantation: Serial intravascular ultrasound analysis from the sirius trial. J Am Coll Cardiol 2004; 43: 1959-1963. (Pubitemid 38686788)
41. Waseda K, Ako J, Kaneda H, Miyazawa A, Shimada Y, Morino Y, et al. Effect of lumen narrowing within sirolimus-eluting stents on proximal and distal vessel segments. Circ J 2008; 72: 534-537. (Pubitemid 351679402)
42. Rao SV, Shaw RE, Brindis RG, Klein LW, Weintraub WS, Peterson ED. On- versus off-label use of drug-eluting coronary stents in clinical practice (report from the American College of Cardiology National Cardiovascular Data Registry [NCDR]). Am J Cardiol 2006; 97: 1478-1481.
43. Ishio N, Kobayashi Y, Takebayasbi H, Iijima Y, Kanda J, Nakayama T, et al. Impact of drug-eluting stents on clinical and angiographic outcomes in dialysis patients. Circ J 2007; 71: 1525-1529. (Pubitemid 47529650)